Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VHR CRISPR/Cas9 KO Plasmid (h): sc-405733
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VHR CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the VHR genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VHR Antibody (F-2): sc-374161
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VHR CRISPR/Cas9 KO Plasmid (h) | sc-405733 | 20 µg | $397.00 |
Overview
Dual specificity protein phosphatase 3 (DUSP3), also known as VHR, is an atypical dual-specificity phosphatase that dephosphorylates phosphotyrosine and phosphoserine/threonine residues on MAP kinases. VHR modulates MAPK/ERK signaling dynamics and contributes to the control of cell-cycle progression, stress responses, and signal termination downstream of growth factor and immune-related cues. By tuning phosphorylation-dependent transcriptional programs, DUSP3 influences proliferation and differentiation phenotypes in human cells. Dysregulated phosphatase activity and altered MAPK pathway control are frequently implicated in cancer biology and inflammatory signaling, making DUSP3 a useful node for mechanistic studies of phosphoregulation.
VHR CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DUSP3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DUSP3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DUSP3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish VHR protein expression.
This CRISPR knockout system enables efficient generation of DUSP3-deficient cell models for investigation of VHR signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DUSP3 exon(s) critical for VHR function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DUSP3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by VHR CRISPR/Cas9 KO Plasmid (h) and VHR CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DUSP3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by VHR HDR Plasmid (h) and VHR HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DUSP3 homology arms to support homology-directed repair at defined DUSP3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.